Verition Fund Management
DALS

Verition Fund Management’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Verition Fund Management’s Portfolio DALS Stock Details DALS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-128,120
Closed -$1.31M – 2816
2023
Q2 		$1.31M Hold
128,120
– – 0.02% 836
2023
Q1 		$1.3M Hold
128,120
– – 0.02% 850
2022
Q4 		$1.28M Hold
128,120
– – 0.02% 810
2022
Q3 		$1.25M Hold
128,120
– – 0.01% 1243
2022
Q2 		$1.24M Buy
128,120
+34,100
+36% +$332K 0.02% 916
2022
Q1 		$917K Buy
+94,020
New +$908K 0.01% 1533

Verition Fund Management's DALS Position: Q3 2023 in Review

Verition Fund Management sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 128,120 shares — an estimated $1.31M sold.

Verition Fund Management first reported a position in DALS in Q1 2022 and held it in 6 quarters. The position peaked at $1.31M in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

  • Verition Fund Management reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Verition Fund Management sold 128,120 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $1.31M.
  • Verition Fund Management first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q1 2022 and held it in 6 quarters.
  • Verition Fund Management's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $1.31M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on Verition Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.